

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 January 2025 (23.01.2025)



(10) International Publication Number
WO 2025/019775 A1

(51) International Patent Classification:

A61K 31/138 (2006.01) A61K 45/06 (2006.01)
A61P 35/00 (2006.01) A61K 9/48 (2006.01)
C07C 15/52 (2006.01) A61K 31/015 (2006.01)
C07C 217/14 (2006.01) A61K 31/14 (2006.01)
C07C 233/18 (2006.01) A61K 31/165 (2006.01)
C07C 271/48 (2006.01) A61K 31/265 (2006.01)

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2024/038753

(22) International Filing Date:

19 July 2024 (19.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/527,801 19 July 2023 (19.07.2023) US

(71) Applicant: ATOSSA THERAPEUTICS, INC. [US/US];
10202 5th Avenue NE, Suite 200, Seattle, WA 98125 (US).

(72) Inventor: QUAY, Steven, Carl; c/o Atossa Therapeutics,
Inc., 10202 5th Avenue NE, Suite 200, Seattle, WA 98125
(US).

(74) Agent: HARWOOD, Melissa, M. et al.; DLA Piper
LLP (US), 701 Fifth Avenue, Suite 6900, Seattle, WA
98104-7029 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: ENDOXIFEN COMPOSITIONS AND METHODS OF USE THEREOF AND SYNTHESIS THEREOF




FIG. 1

(57) Abstract: Described herein are endoxifen compositions comprising novel compounds and methods of use thereof. Methods of synthesis for the compositions are described herein. The endoxifen compositions described herein may exhibit aromatase inhibition activity or estrogen receptor activity. The endoxifen compositions described herein may be useful in the treatment of a condition in a subject, such as cancer.

WO 2025/019775 A1